Replenished the depleted Strategic National Stockpile. • Increased the number of ventilators nearly ten-fold to more than 153,000. • Despite the grim projections from the media and governors, no American who has needed a ventilator has been denied a ventilator. • Increased the number of N95 masks fourteen-fold to more than 176 million. • Issued an executive order ensuring critical medical supplies are produced in the United States. Created the largest, most advanced, and most innovative testing system in the world. • Built the world’s leading testing system from scratch, conducting over 200 million tests – more than all of the European Union combined. • Engaged more than 400 test developers to increase testing capacity from less than 100 tests per day to more than 2 million tests per day. • Slashed red tape and approved Emergency Use Authorizations for more than 300 different tests, including 235 molecular tests, 63 antibody tests, and 11 antigen tests. • Delivered state-of-the-art testing devices and millions of tests to every certified nursing home in the country. • Announced more flexibility to Medicare Advantage and Part D plans to waive cost-sharing for tests. • Over 2,000 retail pharmacy stores, including CVS, Walmart, and Walgreens, are providing testing using new regulatory and reimbursement options. • Deployed tens of millions of tests to nursing homes, assisted living facilities, historically black colleges and universities (HBCUs), tribes, disaster relief operations, Home Health/Hospice organizations, and the Veterans Health Administration. • Began shipping 150 million BinaxNOW rapid tests to states, long-term care facilities, the IHS, HBCUs, and other key partners. Pioneered groundbreaking treatments and therapies that reduced the mortality rate by 85 percent, saving over 2 million lives. • The United States has among the lowest case fatality rates in the entire world. • The Food and Drug Administration (FDA) launched the Coronavirus Treatment Acceleration Program to expedite the regulatory review process for therapeutics in clinical trials, accelerate the development and publication of industry guidance on developing treatments, and utilize regulatory flexibility to help facilitate the scaling-up of manufacturing capacity. • More than 370 therapies are in clinical trials and another 560 are in the planning stages. • Announced $450 million in available funds to support the manufacturing of Regeneron’s antibody cocktail. • Shipped tens of thousands of doses of the Regeneron drug. • Authorized an Emergency Use Authorization (EUA) for convalescent plasma. • Treated around 100,000 patients with convalescent plasma, which may reduce mortality by 50 percent. • Provided $48 million to fund the Mayo Clinic study that tested the efficacy of convalescent plasma for patients with COVID-19. • Made an agreement to support the large-scale manufacturing of AstraZeneca’s cocktail of two monoclonal antibodies. • Approved Remdesivir as the first COVID-19 treatment, which could reduce hospitalization time by nearly a third. • Secured more than 90 percent of the world’s supply of Remdesivir, enough to treat over 850,000 high-risk patients. • Granted an EUA to Eli Lilly for its anti-body treatments. • Finalized an agreement with Eli Lilly to purchase the first doses of the company’s investigational antibody therapeutic. • Provided up to $270 million to the American Red Cross and America’s Blood Centers to support the collection of up to 360,000 units of plasma. • Launched a nationwide campaign to ask patients who have recovered from COVID-19 to donate plasma. • Announced Phase 3 clinical trials for varying types of blood thinners to treat adults diagnosed with COVID-19. • Issued an EUA for the monoclonal antibody therapy bamlanivimab. • FDA issued an EUA for casirivimab and imdevimab to be administered together. • Launched the COVID-19 High Performance Computing Consortium with private sector and academic leaders unleashing America’s supercomputers to accelerate coronavirus research. Brought the full power of American medicine and government to produce a safe and effective vaccine in record time. • Launched Operation Warp Speed to initiate an unprecedented drive to develop and make available an effective vaccine by January 2021. • Pfizer and Moderna developed two vaccines in just nine months, five times faster than the fastest prior vaccine development in American history. • Pfizer and Moderna’s vaccines are approximately 95 effective – far exceeding all expectations. • AstraZeneca and Johnson & Johnson also both have promising candidates in the final stage of clinical trials. • The vaccines will be administered within 24 hours of FDA-approval. • Made millions of vaccine doses available before the end of 2020, with hundreds of millions more to quickly follow. • FedEx and UPS will ship doses from warehouses directly to local pharmacies, hospitals, and healthcare providers. • Finalized a partnership with CVS and Walgreens to deliver vaccines directly to residents of nursing homes and long-term care facilities as soon as a state requests it, at no cost to America’s seniors. • Signed an executive order to ensure that the United States government prioritizes getting the vaccine to American citizens before sending it to other nations. • Provided approximately $13 billion to accelerate vaccine development and to manufacture all of the top candidates in advance. • Provided critical investments of $4.1 billion to Moderna to support the development, manufacturing, and distribution of their vaccines. • Moderna announced its vaccine is 95 percent effective and is pending FDA approval. • Provided Pfizer up to $1.95 billion to support the mass-manufacturing and nationwide distribution of their vaccine candidate. • Pfizer announced its vaccine is 95 percent effective and is pending FDA approval. • Provided approximately $1 billion to support the manufacturing and distribution of Johnson & Johnson’s vaccine candidate. • Johnson & Johnson’s vaccine candidate reached the final stage of clinical trials. • Made up to $1.2 billion available to support AstraZeneca’s vaccine candidate. • AstraZeneca’s vaccine candidate reached the final stage of clinical trials. • Made an agreement to support the large-scale manufacturing of Novavax’s vaccine candidate with 100 million doses expected. • Partnered with Sanofi and GSK to support large-scale manufacturing of a COVID-19 investigational vaccine. • Awarded $200 million in funding to support vaccine preparedness and plans for the immediate distribution and administration of vaccines. • Provided $31 million to Cytvia for vaccine-related consumable products. • Under the PREP Act, issued guidance authorizing qualified pharmacy technicians to administer vaccines. • Announced that McKesson Corporation will produce store, and distribute vaccine ancillary supply kits on behalf of the Strategic National Stockpile to help healthcare workers who will administer vaccines. • Announced partnership with large-chain, independent, and regional pharmacies to deliver vaccines.